News
Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...
Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...
They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...
Wegovy can help people with excess weight and obesity lose weight and improve their health. And you don’t need to drive to a ...
Explore more
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...
Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...
Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...
McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.
Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.
Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results